Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - HAEI.ORG - A La Une - 05/Sep 18:44
Pharvaris provides business update and expands development program for deucrictibant
Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3, the pivotal Phase 3 study of deucrictibant extended-release tablets for the prophylactic treatment of HAE Its intention to pursue clinical development of deucrictibant in a newly named indication, acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH) Presented [...]
Articles similaires
Pharvaris presents data at the Bradykinin Symposium 2024
haei.org - 05/Sep 18:46
Pharvaris presents data at the Bradykinin Symposium 2024 Pharvaris announced a summary of data being presented at the ongoing 7th Bradykinin...
KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE
haei.org - 03/Sep 17:29
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
SBI Foundation Expands Youth for India Fellowship to OCIs, Nepal & Bhutan; Apply Here
times of india - 05/Sep 11:14
The SBI Foundation has expanded the eligibility for its Youth for India Fellowship program to include Overseas Citizens of India (OCIs), Citizens of...
AfDB provides US$ 102.79 million to support farmers through climate resilient Special Agro-Industrial Processing Zones infrastructure
kenyaengineer.co.ke - 13/Sep 20:10
The Board of Directors of the African Development Bank Group (“ADB”) approved $102.79 million for the Multinational (Guinea, Senegal and Togo)...
Intellia to present data from the Phase 2 study of NTLA-2002 for the treatment of HAE at the 2024 ACAAI Annual Scientific Meeting
haei.org - 12/Sep 13:18
Intellia Therapeutics to present data from the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) at the 2024 ACAAI Annual...
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
zacks.com - 09/Sep 15:58
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
zacks.com - 09/Sep 15:58
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
financialpost.com - 15/Sep 12:45
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the...
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
drugs.com - 03/Sep 20:09
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
Les derniers communiqués
-
Aucun élément